Cancer Center Administration: Clinical Cancer Center Protocols
The University of Iowa
Peer Review Status: Not Peer Reviewed
Bladder: Advanced
Phase II study of Cisplatin and Taxol in advanced carcinoma of the
ureothelium (ECOG)
robert-dreicer@uiowa.edu
Phase II study of Paclitaxel plus Caroplatin in patients with
advanced carcinoma of the urothelium (ECOG study)
robert-dreicer@uiowa.edu
Phase II study of Vinblastine, Ifosfamide and Gallium Nitrate in
advanced squamous cell and adenocarcinoma of the urothelium (ECOG
study)
robert-dreicer@uiowa.edu
Bladder: Neoadjuvant
Cystectomy with or without Pre-op M-VAC (ECOG)
robert-dreicer@uiowa.edu
Breast: Node +
Adria Dose Escalation with or without Taxol in CA (Cytoxan/Adria)
regimens, node +, ER/PR+/-/unknown, pre or post-menopausal
(CALGB)
gerald-clamon@uiowa.edu
High Dose Cytoxan/Adria vs sequential Adria followed by Cytoxan in
High Risk patients 0-3 nodes +, pre or post menopausal (CALGB)
gerald-clamon@uiowa.edu
Randomized trial evaluating Taxol following Adriamycin/Cytoxan in
breast cancer patients
mary-spaight@iowa.edu
Double Blind, placebo controlled adjuvant therapy with Tamoxifen
vs Tamoxifen and Fenretinide in postmenopausal women with involved
nodes and positive receptors (CALGB)
gerald-clamon@uiowa.edu
Double Blind, placebo controlled adjuvant therapy with Tamoxifen
vs Tamoxifen and Fenretinide in postmenopausal women with involved
axillary nodes and positive receptors (CALGB)
gerald-clamon@uiowa.edu
Breast: Node -
Path, negative, nodes and ER - negative breast cancer, CMF + TAM
vs AC + TAM (NSABP)
mary-spaight@iowa.edu
High dose Cytoxan/Adria vs sequential Adria followed by Cytoxan in
high risk patients 0-3 nodes +, pre or post menopausal (CALGB)
gerald-clamon@uiowa.edu
Clinical Trial of Tamoxifen and breast radiation in patients with
node-negative, occult, invasaive breast cancer treated by lumpectomy
(NSABP)
mary-spaight@iowa.edu
Breast: Neoadjuvant
Ifosfamide, Navelbine, DDP with G-CSF for Stage III A or B
inflammatory breast cancer
gerald-clamon@uiowa.edu
Randomized trial comparing pre-op Doxorubicin Cyclophosphamide
(AC) vs pre-op AC then pre-op Docetaxel vs pre-op AC then post-op
Docetaxel in patients with operable carcinoma of the breast
(NSABP)
mary-spaight@iowa.edu
Breast: Metastatic
Cytoxan and Navelbine for untreated Stage IV breast cancer
gerald-clamon@uiowa.edu
Taxol at 3 dose levels with or without G-CSF: 0-1 prior treatment
(CALGB study)
gerald-clamon@uiowa.edu
Chemotheraphy and antibody response evaluation (Care): A Phase
III, randomized study of rhuMAb (HER2) combined with chemotherapy in
patients with HER2 overexpression who have not received cytotoxic
chemotherapy for metastatic breast cancer (H0648g )
susan-kambhu@uiowa.edu
An open label extension study with rhuMAb HER2 for Patients whose
metastatic breast cancer progressed during treatment on H0648g
susan-kambhu@uiowa.edu
Phase 2 Study of CI-958 in patients with metastatic breast
cancer
robert-driecer@uiowa.edu
Dose Intense, Multi-agent salvage chemotherapy for women with
Stage IV breast cancer
roger-gingrich@uiowa.edu
Breast: Companion
Linkage of molecular and epidemiological breast cancer
investigations with treatment data (CALGB study)
gerald-clamon@uiowa.edu
Breast: Transplant
PETCy ablative therapy/auto bone marrow transplant for patients
with chemosensitive Stage IV breast cancer
roger-gingrich@uiowa.edu
CAF followed by bone marrow transplant vs consolidation
chemotherapy; Stage II-III, > 10 nodes (CALGB)
gerald-clamon@uiowa.edu
Breast: Prevention
Breast cancer prevention trial (NSABP)
mary-spaight@iowa.edu
Breast: Bone Metastatis
Zoledronate for patients with bone metastatis (breast cancer or
multiple myeloma)
robert-dreicer@iowa.edu
Double blind study of low-dose gallium nitrate for patients with
bone metastases due to breast cancer
robert-dreicer@iowa.edu
Cancer Cachexia
Biochemical study of tumor lipid modification by NIH Omega-3 Ethyl
Ester dietary supplement
c-burns@uiowa.edu
Omega 3 Fatty Acids for cancer cachexia (CALGB)
gerald-clamon@uiowa.edu
Cervix
Phase III randomized study: pelvic radiation with concurrent
chemotherapy vs pelvic and para-aortic radiation for high risk
cervical cancer RTOG
nina-mayr@uiowa.edu
For additional studies involving this disease site, please call the Gynecology Oncology office at (319) 356-2015
CNS
Phase II randomized evaluation of interferon-betas as a single
agent and cis-retinoic acid + interferon-beta in the treatment of
patients with recurrent primary malignant gliomas
todd-janus@uiowa.edu
Post radiation treatment phase III randomized study of DFMO-PCV vs
PCV chemotherapy for malignant gliomas
todd-janus@uiowa.edu
Phase II randomized temozolomide and procarbazine in patients with
glioblastoma multiforme
todd-janus@uiowa.edu
Phase II study of temozolomide in patients with anaplastic
astrocytoma at first relapse
todd-janus@uiowa.edu
Phase III randomized comparison of radiation alone vs
pre-radiation chemotherapy for pure and mixed anaplastic
oligodendrogliomas (RTOG)
nina-mayr@uiowa.edu
Phase II combined modality treatment of primary CNS lymphoma
(RTOG)
nina-mayr@uiowa.edu
An intergroup phase II combined modality treatment of primary CNS
lymphoma (RTOG study)
nina-mayr@uiowa.edu
Merimastat study for patients with glioblastoma multiforme or
gliosarcoma
todd-janus@uiowa.edu
Colon: Operable
Laprascopy-colectomy vs open colectomy for colon cancer
(CALGB)
gerald-clamon@uiowa.edu
Peri-operative 5-FU after resection then 5-FU & levamisole
(CALGB)
gerald-clamon@uiowa.edu
Colon: Advanced
Panorex + 5-FU + Levamisole vs 5-FU + Levamisole in patients with
surgically resected Stage III cancer of the colon
gerald-clamon@uiowa.edu
An open-label randomized phase III study comparing Capecitabine
with 5-Fluorouracil in combination with leucovorin as first-line
chemotherapy inpatients with advanced and/or metastatic colorectal
carcinoma
charles-riggs@uiowa.edu
Colon: Prevention
Colorectal cancer chemo prevention using aspirin (Dukes A and B1,
after surgery, Dukes B2 and C if greater than 5 years disease free)
(CALGB)
gerald-clamon@uiowa.edu
Gastric
Chemotherapy vs observation following resection (CALGB)
gerald-clamon@uiowa.edu
Head and Neck
Phase III trial to preserve the larynx: induction chemotherapy and
radiation therapy vs concomitant chemotherapy and radiation therapy
vs radiation therapy alone (RTOG study)
nina-mayr@uiowa.edu
Phase III randomized comparison of combined modality therapy for
carcinoma of the esophagus, high dose versus conventional dose
radiation therapy (RTOG study)
nina-mayr@uiowa.edu
Phase II Taxol plus Cisplatin & radiation therapy plus
surgery
daniel-berg@uiowa.edu
13-cRA to prevent second primary tumors: Stage 1 (CALGB study)
gerald-clamon@uiowa.edu
Phase III intergroup trial of surgery followed by (1) Radiotherapy
VS. (2) Radiochemotheraphy for resectable high risk Squamous Cell
Carcinoma of the head and neck (RTOG study)
nina-mayr@uiowa.edu
Randomized study of hyperfractionation vs. conventional
fractionation in T2 Squamous Cell Carcinoma of the vocal cord (RTOG
study)
nina-mayr@uiowa.edu
Phase III randomized study to compare 2 x daily accelerated
hyperfractionation, accelerated hyperfractionation with a split and
accelerated fractionation with concomitant boost to standard
fractionation adiotherapy for SCCa of the head and neck (RTOG
study)
nina-mayr@uiowa.edu
Phase III intergroup randomized comparison of combined modality
therapy for carcinoma of the esophagus: high dose vs. conventional
dose radiation therapy (RTOG study)
nina-mayr@uiowa.edu
Prospective randomized phase III clinical trial evaluating the use
of post-operative adjuvant radiotherapy in the treatment of patients
with cutaneous melanoma of the head and neck (RTOG study)
nina-mayr@uiowa.edu
Hemophilia/HIV
Treatment with rVIIIa of hemophiliacs and non-hemophiliacs with
inhibitors to FVIII or FIX for life or limb threatening bleeding
episodes
donald-macfarlane@uiowa.edu
Leukemia: All
Multi-drug, high-intensity, brief-duration chemotherapy for ALL L3
(CALGB)
gerald-clamon@uiowa.edu
PEG-Asparaginase during Chemo for acute ALL - L1/L2 (CALGB)
gerald-clamon@uiowa.edu
Leukemia: AML
Humanized monoclonal antibody antiCD33 therapy for elderly
patients with newly diagnosed AML
george-weiner@uiowa.edu
Leukemia: Companions: AML
Immunologic studies (CALGB)
gerald-clamon@uiowa.edu
Cytogenetic studies (CALGB)
gerald-clamon@uiowa.edu
The CALGB leukemia tissue bank (CALGB study)
gerald-clamon@uiowa.edu
Leukemia: Companions: All
Immunologic studies (CALGB)
gerald-clamon@uiowa.edu
Cytogenetic studies (CALGB)
gerald-clamon@uiowa.edu
Molecular subtypes in Philadelphia chromosome positive patients
(CALGB)
gerald-clamon@uiowa.edu
The CALGB leukemia tissue bank (CALGB study)
gerald-clamon@uiowa.edu
Lung: Small Cell: Extensive
Carboplatin, VP-16, and Taxol with G-CSF, untreated,
Recurrent/Progressive (CALGB)
gerald-clamon@uiowa.edu
Lung: Non-Small Cell: Stage 1
Video assisted wedge resection + radiation therapy in high risk T1
Non- small cell lung cancer (CALGB)
gerald-clamon@uiowa.edu
Randomized trial of 13-cRA to prevent second primary tumors
(CALGB)
gerald-clamon@uiowa.edu
Lung: Non-Small Cell: Stage II/IIIA
Radiation therapy vs radiation therapy/chemotherapy, post op adj.
resected (CALGB)
gerald-clamon@uiowa.edu
Lung: Non-Small Cell: Stage III
Navelbine/DDP vs Gemcitabine/DDP vs Taxol/DDP + radiation therapy
for unresectable, untreated (CALGB)
gerald-clamon@uiowa.edu
Lung: Operable
Pulmonary exercise testing for operative selection of any stage
non-small cell lung cancer or suspected lung cancer (CALGB)
gerald-clamon@uiowa.edu
Lung: Pleural Effusion
Sclerosis of pleural effusions by TALC thoracoscopy vs TALC slurry
(CALGB)
gerald-clamon@uiowa.edu
Lymphoma: AIDS
Low dose Interleukin-2 in AIDS/Lymphoma patients (CALGB study)
gerald-clamon@uiowa.edu
Lymphoma: Hodgkins: Stage 1-11A, 11E
Subtotal nodal radiation therapy vs Adriamycin, Velban and
subtotal nodal radiation therapy (CALGB)
gerald-clamon@uiowa.edu
QOL in Early Stage Hodgkins (CALGB study)
gerald-clamon@uiowa.edu
Lymphoma: Hodgkins: Transplant
BVAC ablative therapy/auto bone marrow transplant for
refractory/recurrent Hodgkins, Non-Hodgkins lymphoma
roger-gingrich@uiowa.edu
Dose escalation of IL-2 as adjuvant post-transplant immune therapy
for Hodgkinís and Non-Hodgkinís lymphomas
roger-gingrich@uiowa.edu
Lymphoma: Non-Hodgkins: Intermediate/High Grade
IDEC C2B8 + CHOP for previously untreated patients with
intermediate or high grade Non-Hodgkinís lymphoma
brian-link@uiowa.edu
Multi-drug, high-intensity, brief-duration chemo (IWF-J)
(CALGB)
gerald-clamon@uiowa.edu
Lymphoma: Non-Hodgkins: Relapse
IDEC-08 (monoclonal antibody) C2B8 for low grade and follicular
B-cell lymphoma in patients who progressed after prior treatment with
C2B8 or who have bulky disease
brian-link@uiowa.edu
Infusional CHOPE; must have received prior CHOPE or CHOP therapy
(CALGB study)
gerald-clamon@uiowa.edu
I-131-Lym 1 for b cell Non-Hodgkin's lymphoma
daniel-kahn@uiowa.edu
Lymphoma: Non-Hodgkins: Transplant
Anti-B4-blocked Ricin vs observation post-autologous bone marrow
transplant (CALGB study)
gerald-clamon@uiowa.edu
Dose escalation of IL-2 as adjuvant post-transplant immune therapy
for Hodgkinís and Non-Hodgkinís lymphomas
roger-gingrich@uiowa.edu
Lymphoma: Non-Hodgkins: Imaging
IMMU-LL2 Fabí labeled with Tc99m for staging and restaging
of NHL
george-weiner@uiowa.edu
Mesothelioma
Gemcitabine for malignant mesothelioma (untreated) (CALGB)
gerald-clamon@uiowa.edu
Multimple Myeloma
Zoledronate for patients with bone metastatis (breast cancer or
multiple myeloma)
raymond-hohl@uiowa.edu
Ovarian
For studies involving this disease site, please call the Gynecology Oncology office at (319) 356-2015
Penile
Phase II Study of 13-cis-Retinoic Acid + Interferon Alpha-2a in
advanced stage penile cancer (ECOG study)
robert-dreicer@uiowa.edu
Prostate: Organ Confined
Intervention vs observation: PIVOT
william-see@uiowa.edu
Casodex vs placebo in patients with early prostate cancer
william-see@uiowa.edu
A Phase III trial comparing whole pelvic irradiation followed by a
conedown boost irradiation only and comparing neoadjuvant to adjuvant
total androgen suppression (TAS) (RTOG study)
nina-mayr@uiowa.edu
Prostate: Stage C
Prostatectomy with or without Adjuvant radiation therapy (ECOG
study)
robert-dreicer@uiowa.edu
Prostate: Metastatic
Comparative study of two dosing regimens of Eulexin
robert-dreicer@uiowa.edu
Intermittent androgen deprivation of patients with stage D2 CaP,
phase III (ECOG)
robert-dreicer@uiowa.edu
Phase II study of IV-Y-90-(MAb) Capromab for patients with occult
prostate cancer
daniel-kahn@uiowa.edu
Phase III trial of orchiectomy/LHRH analog + Flutamide + Suramin +
hydriocortisone vs orchectomy/LHRH analog + Flutamide in patients
with metastatic prostate cancer (ECOG study)
robert-dreicer@uiowa.edu
Prostate: Hormone-Refractory
Phase II study of Deferoxamine and Gallium Nitrate in metastatic
CaP
robert-dreicer@uiowa.edu
Skills in cancer pain control for patients with metastatic CaP
(ECOG study)
robert-dreicer@uiowa.edu
Rectal/Anal
Evaluate the worth of pre-op multi therapy (5-FU-LV &
radiation therapy) in patients with operable Cancer of the rectum
(NSABP)
mary-spaight@iowa.edu
Chemotherapy, then chemotherapy and radiation therapy, T3-T4;
bulky N2-N3, untreated (CALGB)
gerald-clamon@uiowa.edu
Renal
Phase II study of Suramin in patients with metastatic renal cell
carcinoma
robert-dreicer@uiowa.edu
Intron A + 9-cis-Retinoic Acid for advanced RCCa
robert-dreicer@uiowa.edu
ALT for renal cell ca, compassionate use
robert-dreicer@uiowa.edu
Soft Tissue & Solid Tumor
Ice ablation with escalating back to back autlogous bone marrow
transplant for refractory germ cell tumor and soft tissue sarcoma
roger-gingrich@uiowa.edu
A Randomized trial with Pentoxifulline in the treatment of
radiation related soft tissue necrosis (RTOG)
nina-mayr@uiowa.edu
Testes
Phase III of BEP + high dose chemotherapy vs BEP alone (ECOG)
robert-dreicer@uiowa.edu
Thrombocythemia/Thrombocytopenia
An open protocol for the use of Agrelin (anagrelide) for patients
with thrombocythemia
thomas-carlisle@uiowa.edu
An Open Label Study of Novastan (argatroban) evaluating safety and
efficacy in patients with Heparin-Induced Thrombocytopenia/Thrombosis
undergoing Percutaneou Transluminal Coronary Angioplasty, Atherectomy
or Stent Implantation
donald
-macfarlane@uiow.edu
An Open-Label Trial to Deteremine the Effects of CBP-1011 in
patients with Idiopathic Thrombocytopenia Purpura AND A double-blind,
randomized, placebo-controlled trial comparing two doses of CBP-1011
in patients with ITP who are responding to 1000mg of CBP-1011
steven-lentz@uiowa.edu
Thymoma
Etoposide, Ifosfamide, and Cisplatin in the treatment of invasive
thymoma (CALGB)
gerald-clamon@uiowa.edu
Transplant
Allogeneic GVHD prevention: T-cell depletion
roger-gingrich@uiowa.edu
Prophylactic antibacterial antibiotics during bone marrow
transplant
raymond-hohl@uiowa.edu
Phase I Trials:
Pilot study of single photon emission computed tomography using
[18F]2-fluoro-2 deoxyglucose in patients with indetermineate solitary
pulmonary nodules
daniel-kahn@uiowa.edu
Phase I study of Paclitaxel and Gallium Nitrate
robert-dreicer@uiowa.edu
Phase I Gemcitabine for patients with abnormal liver or renal
function (CALGB)
gerald-clamon@uiowa.edu
Randomized, Double-Blind Placebo Controlled Phase I Trial of IV
administered KGF growth factor on colerectal patients treated with
5-FU and leucovorin: cycle 1
gerald-clamon@uiowa.edu
Extention study to KGF 950225: open label of IV KGF in colorectal
carcinoma patients treated with 5-FU and Leucovorin: cycle 2-7
gerald-clamon@uiowa.edu
Follow up study of colorectal carcinoma patients who were
previously enrolled in trials using KGF
gerald-clamon@uiowa.edu
The effects of renal dysfunction on the pharmacokinetics and
pharmacodynamics of Suramin in cancer patients
robert-dreicer@uiowa.edu
Retinoic Acid therapy in post-transplant thrombotic
microangiopathy
steven-lentz@uiowa.edu
Anti-Emetic
Efficacy and tolerability of 2.5 mg Itasetron IV and of 32 mg
Ondansetron IV in the prevention of vomiting and nausea in patients
undergoing Cisplatin containing chemotherapy
robert-dreicer@uiowa.edu
Oral versus IV granisetron for the prior to highly emetogenic
chemotherapy
amy-becker@uiowa.edu
Kytril vs placebo in radiation therapy patients
nina-mayr@uiowa.edu
The University of Iowa Cancer Center Clinical Trials
Office
For further information contact: Linda Annis at 319-353-7252
Next Page | Previous Page | Section Top | Title Page